Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 6/20 | 0.64 |
| ▸ | HTR3A | P46098 | 3/20 | 0.64 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 5/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CLK2 | P49760 | 2/20 | 0.43 |
| ▸ | CLK3 | P49761 | 2/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.42 |
| ▸ | HTR3B | O95264 | 1/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL492223 | 1.00 | CHRNA7 (0.64) | CHRNA7HTR3ADYRK1ANTRK1GSK3B | |
| SCHEMBL492754 | 0.93 | CHRNA7 (0.64) | CHRNA7HTR3ANTRK1KCNH2HTR3E | |
| SCHEMBL4602686 | 0.93 | CHRNA7 (0.64) | CHRNA7HTR3ANTRK1KCNH2HTR3E | |
| SCHEMBL1963576 | 0.92 | CHRNA7 (0.67) | CHRNA7HTR3ADYRK1AGSK3BCLK2 | |
| SCHEMBL491613 | 0.87 | CHRNA7 (0.62) | CHRNA7HTR3ANTRK1HTR3EHTR3B | |
| SCHEMBL2787737 | 0.87 | CHRNA7 (0.64) | CHRNA7HTR3ADYRK1AGSK3BCLK2 | |
| SCHEMBL1963365 | 0.86 | CHRNA7 (0.68) | CHRNA7HTR3ADYRK1AGSK3BCLK2 | |
| SCHEMBL1964521 | 0.85 | HTR3A (0.70) | CHRNA7HTR3ADYRK1AGSK3BHTR3E | |
| SCHEMBL5994352 | 0.85 | HTR3A (0.70) | CHRNA7HTR3ADYRK1AGSK3BHTR3E | |
| SCHEMBL1964257 | 0.85 | HTR3A (0.70) | CHRNA7HTR3ADYRK1AGSK3BHTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319407-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USE THEREOF | XIE WENGE (US) | 2011-12-29 | — | — | US | claimed |
| US-20100105677-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2010-04-29 | — | — | US | claimed |
| EP-1694670-A1 | PYRAZINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST INFECTIOUS DISEASES | GPC Biotech AG (DE) | 2006-08-30 | — | — | EP | claimed |
| US-20050234095-A1 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2005-10-20 | — | — | US | claimed |
| WO-2005058876-A1 | PYRAZINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST INFECTIOUS DISEASES | GPC BIOTECH AG (DE) | 2005-06-30 | — | — | WO | claimed |
| US-8691841-B2 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and use thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2014-04-08 | — | — | US | disclosed |
| US-8691841-B2 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and use thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2014-04-08 | — | — | US | disclosed |
| US-20130217683-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USE THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217683-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USE THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217683-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USE THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2013-08-22 | — | — | US | disclosed |
| US-8486937-B2 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and use thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486937-B2 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and use thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2013-07-16 | — | — | US | disclosed |
| US-20110319407-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USE THEREOF | XIE WENGE (US) | 2011-12-29 | — | — | US | disclosed |
| EP-2336128-A1 | Benzoisothiazoles and preparation and uses thereof | Memory Pharmaceuticals Corporation (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20100105677-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2010-04-29 | — | — | US | disclosed |
| US-20100105677-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2010-04-29 | — | — | US | disclosed |
| US-20100105677-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2010-04-29 | — | — | US | disclosed |
| EP-1735306-A2 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF | Memory Pharmaceuticals Corporation (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20050234095-A1 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2005-10-20 | — | — | US | disclosed |
| WO-2005092890-A2 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319407-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USE THEREOF | CHRNA7, CHRNA5, CHRNA3 | CHRNA7 1/4885HTR3A 352/4885DYRK1A 2487/4885 |
| US-20100105677-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA5, CHRNA3 | CHRNA7 1/4885HTR3A 367/4885DYRK1A 2462/4885 |
| US-20130217683-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USE THEREOF | CHRNA7, CHRNA5, CHRNA3 | CHRNA7 1/4885HTR3A 352/4885DYRK1A 2487/4885 |
| US-20050234095-A1 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof | CHRNA7, CHRNA5, CHRNA3 | CHRNA7 1/4885HTR3A 367/4885DYRK1A 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.